Analyzing Clinical Trial Data with Innovative Advanced Statistical Data Analysis Methods
One2Treat, a spin-off launched by the internationally acclaimed
Belgian SME, IDDI, sought to enhance the accessibility and utility of the
BENEFIT Analysis online platform. This platform incorporates the
Generalized Pairwise Comparisons (GPC) method, an innovative
statistical approach facilitating precision and personalized patient-centric
medicine. The GPC method requires extensive computing resources,
involving systematic pairwise comparisons of clinical trial outcome
measures and simulation of numerous virtual trials. Thus, the primary
challenges for this project included developing a computational system
capable of rapid processing and creating a user interface that accommodates
users with varying statistical expertise - from patients
to experienced statisticians.
The project resulted in a user-friendly web application that
allows users to securely input, format, analyze, visualize, and organize
clinical trial data. Experts can import data from clinical trials,
specify their characteristics, and set default values for the GPC
analysis parameters. The application also includes data validation
checks to ensure data integrity before analysis.
Our UX/UI experts, after a comprehensive study, developed
an intuitive visualization system to select clinical outcome
prioritization and decipher complex results, including various
statistical errors. The platform features an exploration tool
for analysis and a graph creation tool that can be organized
and used in reports. Furthermore, the platform incorporates
a hybrid Python package to implement the GPC analysis method
using optimized high-performance computing techniques.
Our fruitful collaboration with IDDI resulted
in a novel solution that revolutionizes the dynamic analysis
of clinical trials, resulting in personalized medicine.
We offered insightful analysis and strategic guidance,
helping IDDI select the optimal open-source technology.
The successful project outcome eventually led to the
establishment of IDDI's spin-off, One2Treat.